DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION

• US 20110027172A1
• Filed: 12/10/2008
• Published: 02/03/2011
• Est. Priority Date: 12/10/2007
• Status: Abandoned Application

• Current Assignee: Brigham and Women's Hospital Incorporated, Massachusetts Institute of Technology
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Zhang, Liangfang, Farokhzad, Omid C., Wang, Zhuang, Gu, Frank X., Langer, Robert S., Radovic-Moreno, Aleksandar Filip
• Application Number:
  US12/747,040
• Publication Number:
  US 20110027172A1
• Time in Patent Office: Days
• US Class Current: 424/1.29
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: A61K 51/1255 Granulates, agglomerates, microspheres
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo.

Claims

1-8. -8. (canceled)

9. A particle comprising:

a polymeric core comprising a chemotherapeutic agent; and

an outer lipid monolayer comprising a chelator and a radiopharmaceutical agent.

10. The particle of claim 9, wherein the lipid monolayer further comprises a targeting agent.

58. A method of treating a subject comprising administering a therapeutically effective amount of a particle of claim 9.

64. A pharmaceutical composition comprising a particle of claim 9 and a pharmaceutically acceptable excipient.

74. A method of tracking particles in vivo comprising steps of:

administering particles of claim 9 to a subject; and

imaging the subject to determine the location of the particles in the subject.

76. The method of claim 74, wherein the step of imaging comprises imaging the patient by SPECT/CT, MRI, PET, or CT.

11. (canceled)

12. A particle comprising an agent and a radiopharmaceutical agent, wherein at least one of the agents is encapsulated in a polymeric matrix.

13. The particle of claim 12, wherein the agent is a chemotherapeutic agent, an. siRNA, or a radiosensitizer.

17. The particle of claim 12, wherein the agent is a chemotherapeutic agent for the treatment of a proliferative disease, a cardiovascular disease, an infectious disease, an inflammatory disease, an autoimmune disease, a neurological disease, a gastrointestinal disease, a genitourinary disease, or a musculoskeletal disease.

26. The particle of claim 12 further comprising a targeting moiety.

27. The particle of claim 26, wherein the targeting moiety is a protein, peptide, small molecule, lipid, carbohydrate, fatty acid, glycopeptide, glycoprotein, polymer, or polynucleotide.

32. The particle of claim 12, wherein the radiopharmaceutical agent comprises a radioisotope.

33. The particle of claim 12, wherein the radiotherapeutic agent comprises boron-10, fluorine-18, phosphorus-32, copper-64, copper-67, gallium-68, strontium-82, strontium-89, yttrium-90, indium-111, iodine-123, iodine-125, iodine-131, samarium-153, lutetium-177, rhenium-186, rhenium-188, iridium-192, palladium-103, technetium-99m, thallium-201, or actinium-225.

34. The particle of claim 12, wherein the radiotherapeutic agent is associated with the particle through a chelator.

35. The particle of claim 34, wherein the chelator is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), [4-(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]beznoic acid (CPTA), CDTA, ethylenebis(oxyethylenenitrilo)tetraacetic acid, trans-1,2-diaminocyclohexane-N,N,N′

,N′

-tetraacetic acid, diethylenetriaminepentaacetic acid (DTPA), DPPTA, citric acid, 1,3-diaminopropane tetraacetic acid (1,3 DPTA), 2-hydroxyethyl ethylenediamine tetraacetic acid (HEDTA), ethylene bis(oxyethylene nitrilo) tetraacetic acid (EGTA), triethylene tetraamine hexaacetic acid (TTHA), (1R, 4R,7R, 10R)-a,a′

,a″

,a′

″

-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTMA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid) (DOTP), 1,4,7-triazacyclononane (TACN), 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA), 1,4,7,10-tetraazacyclododecane, and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

39. The particle of claim 12, wherein the matrix comprises a polymer selected from the group consisting of poly(lactic acid), derivatives of poly(lactic acid), PEGylated poly(lactic acid), poly(lactic-co-glycolic acid), derivatives of poly(lactic-co-glycolic acid), PEGylated poly(lactic-co-glycolic acid), poly(anhydrides), PEGylated poly(anhydrides), poly(ortho esters) derivatives of pholy(ortho esters), PEGylated poly(ortho esters), poly(caprolactones), derivatives of poly(caprolactone), PEGylated poly(caprolactones), polylysine, derivatives of polylysine, PEGylated polylysine, poly(ethylene imine), derivatives of poly(ethylene imine), PEGylated poly(ethylene imine), poly(acrylic acid), derivatives of poly(acrylic acid), PEGylated poly(acrylic acid), poly(urethane), PEGylated poly(urethane), derivatives of poly(urethane), and combinations thereof.

40. The particle of claim 12, wherein the matrix comprises a polymer selected from the group consisting of polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoaerylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, and combinations thereof.

41. The particle of claim 12, wherein at least one agent is conjugated to a polymer.

43. The particle of claim 12, wherein the greatest dimension of the particle ranges from approximately 1 nm to approximately 100 nm.

46. The particle of claim 12, wherein the zeta potential ranges from −

1 to −

60 mV.

14-16. -16. (canceled)

18-25. -25. (canceled)

28-31. -31. (canceled)

36-38. -38. (canceled)

42. (canceled)

44-45. -45. (canceled)

47-57. -57. (canceled)

59-63. -63. (canceled)

65-73. -73. (canceled)

75. (canceled)

77-82. -82. (canceled)